# A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Study · id `cardio:ct-nct04093752` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04093752](<https://clinicaltrials.gov/study/NCT04093752>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04093752

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 917 participants.

## Technical summary

Registry record NCT04093752. Randomized; no masking; primary purpose treatment. Start 2019-12-09 (actual); primary completion 2021-11-01 (actual). Results posted on 2023-01-06.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 917 participants (enrolled count; ClinicalTrials.gov record NCT04093752, source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)
- Started: 2019-12-09 (actual) (ClinicalTrials.gov record NCT04093752, source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)
- Primary completion: 2021-11-01 (actual) (ClinicalTrials.gov record NCT04093752, source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)
- Completion: 2021-11-24 (actual) (ClinicalTrials.gov record NCT04093752, source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)
- Results first posted: 2023-01-06 (ClinicalTrials.gov record NCT04093752, source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)
- Countries: Australia; China; India; South Korea (ClinicalTrials.gov record NCT04093752, source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04093752-2023-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
- Condition: Type 2 Diabetes
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial (`cardio:pubmed-37231074`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 64f26170d877f55f7b13796d6324f2ae84467613e8dcfe83ac8f9d1f5e67884c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
